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Abstract
Interleukin-11 (IL-11) is a pleiotropic cytokine approved by the FDA against chemotherapy-induced thrombocytopenia.
From a combinatorial selection in a cancer patient, we isolated an IL-11-like peptide mapping to domain I of the IL-11
(sequence CGRRAGGSC). Although this motif has ligand attributes, it is not within the previously characterized interacting
sites. Here we design and validate in-tandem binding assays, site-directed mutagenesis and NMR spectroscopy to show (i)
the peptide mimics a receptor-binding site within IL-11, (ii) the binding of CGRRAGGSC to the IL-11Ra is functionally
relevant, (iii) Arg
4 and Ser
8 are the key residues mediating the interaction, and (iv) the IL-11-like motif induces cell
proliferation through STAT3 activation. These structural and functional results uncover an as yet unrecognized receptor-
binding site in human IL-11. Given that IL-11Ra has been proposed as a target in human cancer, our results provide clues for
the rational design of targeted drugs.
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Introduction
Phage display enables identification of tissue-specific or angio-
genesis-related molecular signatures on blood vessels and thereby
allows ligand-directed delivery [1–10]. Previously we showed,
through direct screening of a combinatorial peptide library in a
cancer patient, that the selective homing peptides localized non-
randomly to specific organs [1]; we also identified a cyclic peptide
(sequence CGRRAGGSC) targeting prostate vasculature and
prostate cancer as an interleukin-11 (IL-11) mimic [1,2]. In a
different line of investigation, Kang et al. [11] proposed a central
role for the IL-11 pathway in the genetic progression of malignant
tumors metastatic to bone. Activation of members of the signal
transduction and activator of transcription (STAT) family, in
particular STAT3, was revealed downstream as a consequence of
the binding of IL-11 to its corresponding receptor [12].
Although IL-11 was initially characterized as a cytokine with
thrombopoietic activity, it was later found to have pleiotropic
effects in multiple tissues [13]. Recombinant IL-11 is an FDA-
approved drug (oprelvekin; NeumegaH) used against chemother-
apy-induced thrombocytopenia (http://www.fda.gov/cder/
biologics/products/opregen112597.htm) [14]. Along with more
than 10 other four-helix bundle cytokines, including interleukin-6
(IL-6), leukemia inhibitory factor (LIF), ciliary neurotrophic factor
(CNTF), oncostatin-M (OSM), and cardiotrophin-1 (CT-1), IL-11
belongs to the gp130 or IL-6-type [15,16]. These cytokines elicit
responses by the assembly of oligomeric signaling complexes that
contain the transmembrane receptor gp130. The structure of IL-
11 has been the subject of molecular modeling and mutagenesis
studies [17–21]. Research has revealed that IL-11 contains three
known receptor-binding sites (I, II and III). Site I of IL-11 binds to
the cytokine-receptor homology region (CHR) in domains 2 and 3
(D2-D3) of IL-11Ra, whereas sites II and III interact with two
separate areas of the gp130 homodimer: the CHR (D2-D3, site II)
and the Ig-like domain (D1, site III) [22–24]. However, no direct
structural analysis is available for either IL-11 or the signaling
complex. In fact, while the X-ray structure of the IL-6 receptor
complex as a hexameric IL-6/IL-6Ra/gp130 ternary complex has
been introduced as a model for IL-11 [25–27], the accuracy of this
extrapolation has actually been challenged because IL-11 and IL-6
share no significant similarity in primary structure and interact
with different receptors presumably through different mechanisms
[28]. A ligand-induced transition from an active tetrameric
complex (including a gp130 dimer) to an inactive hexameric
complex has been proposed for IL-11 [28,29]. Responsiveness to
IL-11 is restricted to cells expressing IL-11Ra in addition to
gp130. In analogy to the IL-6 receptor a (IL-6Ra) and IL-6, it has
been postulated that IL-11Ra ‘‘presents’’ IL-11 to gp130, which is
recruited as a homodimer and leads to the generation of a so-
called high affinity IL-11 receptor complex. This active complex is
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3452the initiating step in the activation of Janus kinase (JAK)/Tyk
tyrosine kinases, which in turn phosphorylate tyrosine residues in
the cytoplasmic region of gp130; these subsequently serve as
docking sites for members of the STAT family of transcription
factors, e.g., STAT3 [12,13,17].
Although the in vivo-selected homing motif CGRRAGGSC
had certain ligand-specific attributes [1,2], the corresponding
location within the native cytokine is not in an established
interacting site between IL-11 and IL-11Ra [17–28]. We
hypothesized and subsequently confirmed that this peptide motif
functions as a new binding site within IL-11. Tandem site-directed
mutagenesis, binding assays, nuclear magnetic resonance (NMR)
spectroscopy, and signal transduction analysis strongly support the
conclusion that this peptide sequence is indeed a previously
unrecognized receptor-interacting site within human IL-11.
Results
Selected sequence-binding to the IL-11 receptor
complex is specific and does not include gp130
We have previously established that phage displaying the motif
CGRRAGGSC specifically interacts with IL-11Ra; this interac-
tion was inhibited by recombinant IL-11 in a concentration-
dependent manner but not by IL-1b [1,2]. Because the functional
IL-11 receptor complex appears to be a multi-heterodimer
composed of IL-11, IL-11Ra, and gp130 [15], we first evaluated
whether the selected IL-11-like motif [1,2] would bind to IL-11Ra,
to gp130, or to both. For this purpose, we coated plates with the
following protein: IL-11Ra, gp130, or the leptin receptor (an
unrelated gp130 partner). Bovine serum albumin (BSA) served as a
negative control for the binding assay (Figure 1A).
CGRRAGGSC-phage did not bind above background levels to
immobilized gp130, in comparison to its significant binding to
human IL-11Ra (Figure 1A), data indicating no phage binding to
gp130 alone. Moreover, CGRRAGGSC-phage binding to the
leptin receptor or to BSA was undistinguishable from that of
untargeted control phage. These results establish that the
CGRRAGGSC peptide only binds to IL-11Ra in the receptor
complex when individual subunits are analyzed. We next showed
that CGRRAGGSC-phage binding to IL-11Ra is mediated by the
IL-11-like motif, because synthetic CGRRAGGSC inhibited
binding of the cognate phage in a concentration-dependent
manner (Figure 1B).
NMR spectroscopy of the targeted peptide-receptor
interaction
NMR is a particularly suitable methodology to study medium-
to-low affinity binding [30,31], which is often the case for the
interaction between peptide ligands identified by phage display
(such as CGRRAGGSC peptide and IL-11Ra). By measuring
subtle changes in the NMR parameters of the ligand (such as
chemical shifts and relaxation times) one can probe binding events
that occur at the mM to mM concentration range due to the fast
exchange between the bound conformation and free form of the
ligand. Once the fast exchange regiment is reached an excess of
ligand (mM) over the receptor (mM) can be employed for the
measurements. Fast exchange condition is frequently present in
binding studies involving peptides selected from phage display
libraries because of their inherent medium to low affinity range
[30–32]. Thus, to characterize the structural basis of the
interaction between the peptide CGRRAGGSC and IL-11Ra,
we applied NMR-spectroscopy [30,32]. We began by analyzing
the structural behavior of the free synthetic peptide
CGRRAGGSC by proton NMR. The one-dimensional (1D-
1H-
NMR) spectrum displayed broad lines at 25uC (Figure S1A)
indicating the presence of conformational exchange among
multiple CGRRAGGSC conformers. Although the resonance line
became more defined at 5uC, conformational exchange persisted
at low temperatures (Figure S1A); indeed, the occurrence of
multiple conformers is not uncommon in this setting and has not
precluded the study of ligand receptor interactions [30]. In the
case of CGRRAGGSC peptide almost all the resonances in the
spectra were unambiguously assigned to the individual residues of
the peptide based on two-dimensional proton spectra (2D-
1H-
NMR) TOCSY and NOESY (Table S1 and S2).
Having characterized the structural behavior of the
CGRRAGGSC peptide in solution and assigned its resonances
in the NMR spectra, we next set up binding assays [30] to gain
insight into the basis for receptor binding to the ligand peptide.
The spectrum of free CGRRAGGSC was compared to those of
CGRRAGGSC in the presence of IL-11Ra (under a molar excess
of peptide of ,16-, 33- and 66-fold), and changes in chemical shift
(Dd) were analyzed (Figure 2A). Although the precise mapping of
the residues in CGRRAGGSC could not be achieved from the
1D-
1H-NMR spectra due to receptor peak overlap, the interaction
Figure 1. Binding of IL-11-like peptides to IL-11Ra. (A)
CGRRAGGSC-phage binding to the individual receptor components of
the IL-11 receptor complex: IL-11Ra and gp130. Leptin receptor and
BSA served as negative controls for binding. (B) Concentration-
dependent binding inhibition of CGRRAGGSC-phage to IL-11Ra by
the cognate synthetic peptide. Bars represent mean6standard error of
the mean (SEM).
doi:10.1371/journal.pone.0003452.g001
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PLoS ONE | www.plosone.org 2 October 2008 | Volume 3 | Issue 10 | e3452Figure 2. Structural basis of the interaction between CGRRAGGSC and IL-11Ra. (A) Effect of the CGRRAGGSC peptide concentration upon
biding to IL-11Ra. Amide region of 1D-
1H-NMR spectra of increasing molar concentrations of the peptide CGRRAGGSC binding to IL-11Ra (6 mM) is
shown (blue). CGRRAGGSC peptide alone (400 mM) and the spectrum of IL-11Ra alone are also shown (in red and black, respectively). The appearance
of arginine side-chain resonances (not seen in the spectrum of the peptide alone) is indicated (*). (B) Chemical shift changes induced on the
CGRRAGGSC resonances by binding to IL-11Ra. The 2D-
1H-NMR TOCSY spectra of CGRRAGGSC (400 mM) either alone (black) or in the presence of
6 mM IL-11Ra (red) are shown. Single-headed and double-headed arrows indicate chemical shift changes and the appearance of new spin-systems,
respectively. (C) Composition of amide region of 1D-
1H-NMR and corresponding 2D-
1H-NMR TOCSY spectra of the CGRRAGGSC peptide at 5uC (left),
at 25uC (middle) and at 25uC in the presence of IL-11Ra (right). The circles with dotted lines and the arrow indicate arginine resonances.
doi:10.1371/journal.pone.0003452.g002
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alterations and new spin systems (Figures 2A–C). Such changes are
indicative of binding and are suggestive that multiple residues
contribute to the interaction. Moreover, the binding equilibrium
was dependent on peptide concentration and consistent with a fast
exchange rate (ms range) due to the resonances of free and bound
forms of the peptide were detected as average bands (Figure 2A).
To calculate the individual chemical shift changes (Dd) induced
by IL-11Ra upon each of the hydrogen atoms of CGRRAGGSC,
we compared the individual 2D-
1H-NMR TOCSY spectra
obtained in the absence and presence of IL-11Ra (molar peptide
excess ,66-fold) (Figure 2B and Table 1). These spectra were also
used for the analysis of new spin systems (Figures 2B and 2C). In
the 2D-
1H-NMR TOCSY the receptor NMR signal was filtered
during the 80 ms spin lock, resulting in a cleaner analysis of
chemical shift perturbation. We observed that most individual
resonances in CGRRAGGSC showed significant Dd upon binding
to IL-11Ra (Figure 2B and Table 1), a result indicating that nearly
all residues within CGRRAGGSC participate in the binding to the
receptor in a direct or indirect manner. The most prominent Dd
(.10 Hz) involved the a-hydrogen atoms of the Gly
7 and of the
Cys residues (which could not be unambiguously assigned and
here is referred to as Cys
1/9). However, Dd.5 Hz for residues
Cys
1, Gly
2, Gly
6, Ser
8, and Cys
9 were also noteworthy. The new
spin systems observed in the 1D-
1H-NMR spectra (Figure 2A) also
appeared in the TOCSY spectra, and were assigned to Cys
1/9,
Arg
3/4, and Ala
5 (Figure 2B, double-headed arrows). These new
spin systems map to the peptide region that undergoes a complex
conformational equilibrium in the free state. This result suggests
that, upon binding to IL-11Ra, the segment Cys-s-s-Cys-Gly-Arg-
Arg-Ala in CGRRAGGSC becomes conformationally con-
strained, resulting in a gain-of-structure and corresponding loss-
of-freedom for CGRRAGGSC in the bound state. Consistently,
similar results were observed by comparing the 1D-
1H-NMR and
the 2D-
1H-NMR TOCSY spectra of CGRRAGGSC at 5uC and
25uC (Figure 2C). Arg
3, Arg
4 and Ala
5 resonances could only be
detected in the spectra at 5uC (Figure 2C, left panel) but not in the
spectra at 25uC (Figure 2C, middle panel), again indicative that
conformational variability plays a role when detecting such spin
systems which has been recently reported [31,33–35]. However,
upon binding to IL-11Ra, resonances corresponding to Arg
3, Arg
4
and Ala
5 were also observed in the spectra at 25uC (Figure 2C,
right panel).
Taken together, our NMR data indicate that conformational
variability plays a structural role in CGRRAGGSC peptide
interaction with IL-11Ra and suggest that: (i) most residues in
CGRRAGGSC change their conformation upon binding to IL-
11Ra, (ii) the Cys-s-s-Cys-Gly-Arg-Arg-Ala domain of the peptide
undergoes a receptor-dependent gain-of-structure, (iii) the motif
Gly-Gly-Ser-Cys-ss-Cys encompasses a candidate site for direct
interaction of the peptide with IL-11Ra, and (iv) that the residues
Gly
7 and Ser
8, in agreement with the mutational studies (described
below), are also relevant for binding.
Functional analysis of wild-type and site-directed IL-11
mutants
In previous work, other investigators have produced recombi-
nant proteins containing point mutations to unveil functional
attributes of the native IL-11; notably, point mutations within the
site containing the CGRRAGGSC sequence have not been
reported [17–21]. Thus, to further demonstrate that residues 112–
117 represent a protein-interacting site, we first attempted to
generate a series of recombinant site-directed alanine-scan
mutants of the motif RRAGGS within human IL-11.
Whereas DNA sequencing (data not shown) and SDS-PAGE
analysis (Figure 3A) showed that the wild-type and mutant IL-11
recombinant proteins were produced with the expected molecular
weight, a number of IL-11 mutants presented steric hindrance and
misfolding aberrances. Such inherent technical limitation of any
mutational study is evident from the lack of epitope accessibility
observed in studies with anti-IL11 antibodies (Figure 3B and data
not shown). Despite these potential issues, we next used ELISA to
assess the attributes of IL-11 point mutants (residues 112–117) for
their ability to bind to the IL-11Ra. Mutation of the residues
Arg
113 (R113A), Gly
115 (G115A), and Ser
117 (S117A) markedly
reduced binding of IL-11 to the receptor, relative to the wild-type
sequence (86, 71, and 86% binding inhibition, respectively),
whereas mutation of residues Arg
112 (R112A) and Gly
116 (G116A)
produced only a moderate effect (43 and 29% binding inhibition,
respectively) (Figure 3C). These data indicate that most of the
residues within the RRAGGS motif participate in the binding to
IL-11Ra; however, Gly
115 and Ser
117 are likely the key residues
mediating the ligand-receptor interaction. Thus, consistent with
our working hypothesis, the alanine-scan mutants did show
reduced, albeit specific, binding to the corresponding receptor,
IL-11Ra (Figure 3C).
The role of residue Arg
113 is somewhat problematic to evaluate
from ELISA, because this mutation affected the reactivity of the
anti-IL-11 antibodies. To rule out the possibility that the observed
reduction in binding of the IL-11 mutants to the IL-11Ra was
secondary to misfolding of the full-length protein and/or steric
hindrance, we devised an alternative ligand-receptor assay based
on site-directed mutagenesis of peptide-targeted phage. Single-
residue alanine scanning mutagenesis of the CGRRAGGSC
phage were produced and binding of each phage to immobilized
IL-11Ra was tested in a functional assay (Table 2). Mutation of
Arg
4, Gly
7 and Ser
8 residues in CGRRAGGSC phage abrogated
binding to the receptor (Table 2), whereas mutation of residues
Arg
3 and Gly
6 did not inhibit binding but reduced the
CGRRAGGSC-receptor interaction by over 70%. These data
are in agreement with the NMR and the IL-11 site-directed
mutagenesis studies and indicate that most residues within the
RRAGGS motif participate in the interaction with IL-11Ra.
Moreover, the data identify a central role for the Ser
8 residue in
CGRRAGGSC (corresponding to the Ser
117 of IL-11) in binding
to the receptor and indicate that both glycine residues are
important for interaction with IL-11Ra. In conclusion, residues
112–117 in human IL-11 comprise a structural and functional site
for the interaction of the protein with its receptor.
The synthetic peptide CGRRAGGSC induces cell
proliferation
Having shown that the motif RRAGGS represents a relevant
site within human IL-11, we proceeded to determine whether the
corresponding synthetic peptide is biologically active. IL-11
induces concentration-dependent proliferation when incubated
with human TF-1 leukemia cells ([36]; and data not shown). Thus,
we evaluated whether the corresponding synthetic CGRRAGGSC
peptide mimics IL-11 in its stimulation of these cells upon binding
to the IL-11Ra. We first exposed TF-1 cells to the CGRRAGGSC
peptide in the presence or absence of either IL-11 or GM-CSF
(positive control) under pre-determined conditions in which IL-11
induces optimal cell proliferation. Soluble CGRRAGGSC peptide
induced a potent growth-stimulatory effect on TF-1 cells, alone
and in the presence of IL-11 (Figure 4A, left panel) or GM-CSF
(data not shown), whereas no effect was observed on control (non-
IL-11Ra-expressing) cells (Figure 4A, right panel) [2]. This
peptide-induced proliferative effect was more pronounced for
Functional IL-11 Peptide Mimic
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CGRRAGGSC plus GM-CSF (data not shown); an unrelated
cyclic control peptide did not show detectable effects by itself or in
combination with IL-11. Next, to evaluate whether
CGRRAGGSC-induced proliferation is dependent on cell surface
IL-11Ra, we used the corresponding soluble receptor, sIL-11Ra,
as a molecular decoy for peptide binding. Cell proliferation
induced by CGRRAGGSC was lower in the presence of sIL-11Ra
(t-test, P,0.005) but not in the presence of a control soluble
receptor (Figure 4B). Of note, less inhibition was observed when
cells were cultured with CGRRAGGSC, sIL-11Ra and IL-11,
Figure 3. Binding of wild-type or site-directed mutants of IL-11
to IL-11Ra. (A) Purified recombinant proteins were analyzed by
Coomassie staining. (B) Western blot analyses with polyclonal anti-IL-11
and anti-GST antibodies. (C) Recombinant GST fusion proteins (alanine
scan mutants of residues 112–117 of IL-11, wild-type IL-11, GST alone, or
rhIL-11) were coated in triplicate overnight and incubated with IL-11Ra.
Binding was detected with anti-Fc antibody. Bars represent mean6-
standard error of the mean (SEM).
doi:10.1371/journal.pone.0003452.g003
Table 1. Individual chemical shift changes in CGRRAGGSC
upon interaction with IL-11Ra.
Residue Hydrogen Dd (Hz)
Cys
1 HN 2.1
Ha 2.1
Hb20 . 0
Hb3 28.9
Cys
1/9 HN N.D.
Ha 217.0
Hb N.D.
Gly
2 HN N.D.
Ha2 5.8
Ha3 N.D.
Arg
3 HN N.D.
Ha 1.0
Hb2 22.8
Hb3 23.1
Hc 21.0
Hd 24.1
Arg
4 HN N.D.
Ha 22.7
Hb2 22.8
Hb3 23.1
Hc 21.0
Hd 24.1
Ala
5 HN N.D.
Ha 22.4
Hb 0
Gly
6 HN 5.8
Ha2 5.2
Ha3 5.0
Gly
7 HN 3.0
Ha2 .12
Ha30
Ser
8 HN N.D.
Ha 6.4
Hb 21.2
Cys
9 HN 9.0
Ha 21.6
Hb1 21.8
Hb2 21.0
Differences in chemical shift change (Dd=dfree2dbound) were determined in free
CGRRAGGSC (400 mM) and in the presence of IL-11Ra (6 mM) calculated from
2D-
1H-TOCSY. Bold and italicized numbers represent chemical shift changes
greater than 5 Hz. Labile resonances were not detected (N.D.) due to fast
solvent exchange or receptor peak overlap.
doi:10.1371/journal.pone.0003452.t001
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complex IL-11-sIL-11Ra (Figure 4B). These results show that the
synthetic peptide CGRRAGGSC can induce cell proliferation by
itself, possibly acting as an IL-11Ra-stimulatory ligand.
STAT3 phosphorylation mediates CGRRAGGSC-induced
cell proliferation
IL-11 binding to IL-11Ra and glycoprotein 130 (gp130)
mediates signal transduction through STAT3 activation; therefore,
we next evaluated whether the CGRRAGGSC peptide might
stimulate cell proliferation by activation of the same pathway. To
that end, we examined ligand-mediated STAT3 activation in
serum-starved TF-1 cells incubated in the presence of IL-11,
CGRRAGGSC peptide, or an unrelated cyclic control peptide.
Despite serum starvation, weak STAT3 (P-Tyr
705) baseline
activation was detected in unstimulated TF-1 cells (Figure 5).
Twenty minutes incubation with either CGRRAGGSC or IL-11
(positive control) led to STAT3 phosphorylation (Figure 5A),
which increased in a concentration-dependent manner (Figure 5B).
Similar effects were observed for IL-11 in combination with
CGRRAGGSC or an unrelated cyclic peptide (but not for the
control peptide alone) (Figure 5A). These data uncover a potential
molecular mechanism underlying CGRRAGGSC-induced prolif-
eration via activation of the IL-11 receptor complex through
STAT3 and indicate that this site within IL-11 is functionally
active for binding and signal transduction.
Discussion
Through direct selection of peptide libraries in patients
[1,37,38], we isolated a ligand peptide mimicking IL-11 from
the prostate vasculature [1] and proposed the IL-11Ra as a target
during the progression of prostate cancer [2]. Here we elected to
explore the structural and functional attributes of this putative
protein-protein interaction because the currently known binding
sites within human IL-11 [22–24] do not encompass the selected
peptide sequence within the native protein (Figure 6).
We used complementary strategies such as site-directed
mutagenesis and NMR-based studies to establish that all six
residues of the RRAGGS motif are likely required for binding to
IL-11Ra. Because NMR analysis did not unambiguously reveal
which of the arginine residues (Arg
3 or Arg
4) participates in
receptor binding, studies based on targeted phage alanine
scanning and IL-11 site-directed mutagenesis were indicated. In
both cases, Arg
4 turned out to be the key residue. All three
methods also suggested that Gly and Ser residues contribute to the
level of IL-11Ra binding by the ligands. Indeed, the Ser
8 mutation
abolished the binding of CGRRAGGSC to IL-11Ra; the Dd
observed in Ser
8 induced by binding to IL-11Ra corroborated this
result.
We have attempted to generate and interpret molecular models
of IL-11 based on high-resolution structural studies available for
other gp130-type cytokines, including IL-6 [21,39] and CNTF
[21,40] and on mutagenesis of IL-6, CNTF and LIF [41–43]. In
the case of the binding site for IL-11Ra or site I, directed
mutagenesis of specific residues at the C-terminus of helix D and
the AB loop established that these regions participate in receptor
binding and cytokine-mediated bioactivity [17–21], analogous to
IL-6 [39]. Both locations are positioned close to each other in
these models and occupy the C-terminus of the four-helix bundle
structure, which is situated opposite the BC loop. Similar
structural and mutagenesis-based studies on gp130-type cytokines
(vIL-6, CNTF and LIF) implicated residues within the BC loop in
receptor recognition and bioactivity [44–46]. However, such
residues were part of site II or site III (for interaction with gp130 or
gp130/LIF receptor), and not site I. Notably, the crystal structure
of the IL-6 receptor complex hexamer demonstrated no role in IL-
6 receptor binding for the BC loop, which is facing the N-terminal
region of D2 in the second gp130 molecule [47]. Our data show
that CGRRAGGSC is a peptide mimic of IL-11, and as such is
capable of recognizing and binding to IL-11Ra to activate cell
signaling and proliferation. Although it is generally assumed that
the model for the cell membrane-bound IL-11 receptor complex
would be similar to that for IL-6 [26,47], certain structural
characteristics in the complex subunits may actually diverge
significantly. For instance, we noticed the existence of four
unreported leucine-zippers within IL-11 (three of them extending
from the BC loop through the helix C, Figure 6). They have no
clear parallel among most other gp130-type cytokines (only OSM
and CT-1 appear to contain one of such regions). Moreover, there
are two IL-11Ra membrane-bound isoforms that differ by the
presence or absence of a cytoplasmic domain, whereas IL-6Ra has
only one form with a longer cytoplasmic tail [48]. Such isoforms
could participate in the formation of a receptor complex unlike
those observed in the IL-6Ra complex formation. Future detailed
X-ray crystallography of the IL-11 receptor complex will further
elucidate these fine structural features.
Functionally, the IL-11 mimic peptide CGRRAGGSC showed
biological effects mediated by IL-11Ra (concentration-dependent
stimulation of cell proliferation) both in the presence and in the
absence IL-11. Furthermore, CGRRAGGSC-mediated cell pro-
liferation in the presence of sIL-11Ra was reduced, and to a
greater degree in the presence of native IL-11, but was not affected
by an unrelated control receptor. Based on these findings, one
might speculate on an interaction between the peptide
CGRRAGGSC and the complex IL-11/IL-11Ra. Indeed, the
soluble peptide CGRRAGGSC was found to induce STAT3
phosphorylation in the same manner as the IL-11 native cytokine.
These results have biological precedent in other systems. Wrighton
et al. [49] isolated peptides that bind to and activate the
erythropoietin receptor (EPOR); crystallographic analysis of the
receptor complex revealed a peptide that generated a functional
symmetric arrangement of the EPOR [50]. Cwirla et al. [51]
selected peptide agonists for the thrombopoietin receptor and
proposed an activation mechanism. Recent studies have also
shown that orientation and residence time of ligand-receptors must
be considered for activation [52,53]. Moreover, peptides selected
for binding to certain receptors bind to several sites on the receptor
Table 2. Phage binding to IL-11Ra.
Peptide Sequences Relative Binding
a
CGRRAGGSC
b +++
CARRAGGSC ++
CGARAGGSC +
CGRAAGGSC 2
CGRRAAGSC +
CGRRAGASC 2
CRGSGAGRC
c 2
Negative control 2
aRatio of Binding to IL-11Ra/Binding to BSA: +++: .30; ++: 15–30; +: 6–15; 2:
,6.
bPositive control.
cScrambled control; Negative control, insertless.
doi:10.1371/journal.pone.0003452.t002
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rather than multimerization [54].
From a supra-molecular viewpoint, IL-11 receptor complex
formation is in all probability intricate: the ligand cytokine (IL-11)
may need to bind first to a presenting receptor subunit (IL-11Ra)
and subsequently recruit a dimer of signaling subunits (i.e., gp130).
Studies of the related IL-6 receptor complex support the
contention that preformed inactive dimers of receptor subunits
exist in cell membranes [28,55,56]. Previous reports determined
that gp130-dimerization is not sufficient for receptor activation
and that active conformational adjustment is required for a
biological response [14,57–59]. Therefore, it is possible that the
soluble peptide CGRRAGGSC in complex with IL-11Ra might
strengthen gp130-dimerization and/or induce a signaling-compe-
tent conformation.
The strength of combining various functional assays (site-
directed mutagenesis of native proteins in tandem with ELISA plus
peptide-alanine scanning in tandem with targeted phage binding
assays) with structural studies (NMR-based spectroscopy of the
peptide-receptor interaction) may overcome some of the limita-
tions of mutational studies in the determination of binding sites of
ligand-receptor interactions (such as difficult gene/protein expres-
sion, and mutant protein misfolding or steric hindrance).
In summary, we have shown that (i) the RRAGGS sequence
(corresponding to a site within human IL-11, residues 112–117)
mimics a candidate protein-binding site within IL-11, (ii) the
molecular interaction between the peptide CGRRAGGSC and
IL-11Ra is functional, and (iii) the IL-11-like motif induces
proliferation of responsive cells through IL-11Ra-mediated
STAT3 activation.
Materials and Methods
Reagents
The following antibodies were obtained commercially: mono-
clonal anti-IL-11 (R&D Systems, Minneapolis, MN), polyclonal
Figure 4. Biological effects of the IL-11-like peptide CGRRAGGSC on IL-11-responsive cells. (A) Concentration-dependent proliferative
response to CGRRAGGSC is shown on IL-11Ra-expressing human TF-1 leukemia cells in the absence or presence of IL-11 (left panel). No response is
observed on non-IL-11Ra-expressing control cells (right panel). (B) Soluble IL-11Ra-mediated inhibition of the proliferative effect induced by 150 mM
CGRRAGGSC peptide (and by IL-11). * t-test, P,0.005. Bars represent mean6standard error of the mean (SEM).
doi:10.1371/journal.pone.0003452.g004
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glutathione S transferase (GST) (Amersham Pharmacia Biotech.
Piscataway, NJ), anti-human Fc HRP-conjugated (Sigma-Aldrich,
St. Louis, MO), and anti-STAT3 or anti-phospho-STAT3 (P-
Tyr
705) (Cell Signaling Technology, Beverly, MA). Recombinant
proteins (rhIL-11, IL-11Ra, gp130 and LeptinR) were purchased
Figure 5. The IL-11-Like peptide CGRRAGGSC induces STAT3 activation upon binding to IL-11Ra in a concentration-dependent
manner. (A) Proliferation of human TF-1 leukemia cells induced by CGRRAGGSC is associated with STAT3 phosphorylation, as assessed with an anti-
STAT3-P-Tyr
705 antibody. (B) CGRRAGGSC peptide-induced activation of STAT3 is concentration dependent. No effect is observed with a control
peptide. To avoid inter-experimental variation, the lysate was divided in two: one-half of the lysate was immunoblotted with an anti-STAT3-P-Tyr
705
antibody whereas the other half served to determine the total amount of STAT3 (as a surrogate for protein loading) with a specific anti-STAT3
antibody. Note that the commercial HeLa cell extracts serving as controls display only the /-STAT3 band.
doi:10.1371/journal.pone.0003452.g005
Figure 6. Residues identified within known human IL-11 binding sites. Arrowheads indicate human IL-11 residues predicted (through site-
directed mutagenesis) to be ligand-receptor binding sites; solid colors specify residues that are critical for binding [17–21]. Residues 112–117
corresponding to the IL-11-like motif [1,2] described in this work are highlighted in yellow. The basic scheme of human IL-11, as shown here, has been
modified from reference [47].
doi:10.1371/journal.pone.0003452.g006
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synthesized and cyclized at AnaSpec (San Jose, CA). Phage
displaying the peptide CGRRAGGSC or its scrambled version
CRGSGAGRC have been described [1,2].
Phage binding assay
CGRRAGGSC phage recovered in vivo served for in vitro
binding to IL-11Ra and gp130 [1,2]. IL-11Ra, gp130 or control
leptin receptor (the extracellular domain fused to the Fc region of
human IgG; R&D Systems) were coated on microtiter wells. [60].
Proteins were immobilized (2 mg/ml) on microtiter wells overnight
at 4uC, washed twice with phosphate buffered saline (PBS),
blocked PBS containing with 3% bovine serum albumin (BSA) for
2 h at room temperature, and incubated with 10
9 TU of targeted
or negative control phage (insertless). After 1 h at room
temperature, wells were washed twelve times with PBS, and
bound phage were recovered by bacterial infection and plated as
described [1].
NMR spectroscopy
NMR experiments were acquired on a 600 MHz spectrometer
(Bruker Avance DRX). CGRRAGGSC (400 mM) chemical shift
assignment was performed in 50 mM sodium phosphate buffer
containing 5 mM sodium azide and 10% D2O. Two-dimensional
spectra were collected with 1,024 transients. NOESY spectra [61]
were acquired with 150 ms mixing time. Spectra were collected
(4,096 F1 points, 512 F2 points). TOCSY spectra (spin-lock
time=80 ms) were acquired with MLEV-17 [62] (4,096 F1 points,
512 F2 points). Water suppression was achieved with WATER-
GATE [63]. One-dimensional
1H-NMR spectra of peptide in the
presence of IL-11Ra (6 mM) were obtained. Chemical shift
perturbations were followed by TOCSY and NOESY by
comparison of the spectra of CGRRAGGSC (400 mM) free in
solution or in the presence of IL-11Ra. Analysis of the 1D-
1H-
NMR spectra with increasing concentrations of CGRRAGGSC
(up to 400 mM) revealed no significant resonance shifts (Figure
S1B), data indicating that the peptide was monomeric. Sodium
2,2-dimethyl-2-silapentane-5-sufonate (70 mM) served as a stan-
dard for precise spectral overlapping.
Protein expression and purification
IL-11 alanine-scanning mutants were expressed in E. coli BL21
and purified from inclusion bodies. In brief, cells were cultured in
26YT media supplemented with 200 mg/ml carbenicillin until
OD595 nm,0.6, at which point GST expression was induced with
1 mM IPTG. After 4 h of induction, bacteria were collected by
centrifugation (5,000 g for 10 min) and lysed with BugBuster
reagent (EMD Biosciences, CA) according to the manufacturer’s
recommendations. GST-IL-11 fusion proteins within the inclusion
body fractions were collected by centrifugation at 28,000 g for
30 min and washed with 8 M urea in PBS. The purified inclusion
bodies were solubilized in 6 M guanidine-HCl, 50 mM Tris-HCl
pH 8, 100 mM NaCl, 10 mM EDTA, and 10 mM DTT at 0.5 to
1 mg/ml (solubilization buffer). Purified recombinant proteins
were analyzed by staining with Coomassie Brilliant Blue, and
Western blot with anti-IL-11 and anti-GST antibodies. To
confirm the proper folding of the IL-11-GST mutants, Western
blot with one polyclonal anti-IL-11 and two monoclonal anti-IL-
11 antibodies were performed (data not shown).
IL-11 site-directed mutagenesis
The human IL-11 cDNA clone was obtained from Invitrogen
(Clone ID 4476678). We designed specific PCR primers containing
BamHIa n dNotI for PCR amplification and directional cloning of the
IL-11 open reading frame in the pGEX4T-1 prokaryotic expression
vector (Amersham). The GST-IL-11 clone was sequenced to confirm
the fusion of both proteins. We used the GST-IL-11 plasmid as a
template for the generation of the IL-11 mutants. PCR mutagenesis
was performed in a reaction volume of 50 ml that included 1 mL
plasmid DNA (20 ng/ml), 10 pmol primers, 200 mM dNTPs, and 2.5
U Pfu Ultra high fidelity DNA polymerase (Stratagene, La Jolla, CA).
Sense and antisense primers were designed to substitute nucleotides
and to introducean alanine residue. The oligonucleotides used for IL-
11 mutagenesis were: R112A, 59-CTGCGGCACGTGCAGTG-
GCTGGCCCGGGCAGGTGGCTCTTCCCTG-39; R113A, 59-
CGGCACGTGCAGTGGCTGCGCGCGGCAGGTGGCCTC-
TCCCTGAAG-39; G115A, 59-GTGCAGTGGCTGCGCCGGG-
CAGCTGGCTCTTCCCTGAAGACCCTG-39; G116A, 59-
CAGTGGCTGCGCCGGGCAGGTGCCTCTTCCCTGAAG-
ACCCTGGAG-39; S117A, 59-TGGCTGCGCCGGGCAGGT-
GGCGCTTCCCTGAAGACCCTGGAGCCC-39. A preliminary
denaturation step at 95uC for 3 min was followed by 20 cycles of
PCR. These PCR cycles consisted of 30 s of denaturation at 95uC,
1 min of annealing at 65uC and 10 min of extension at 72uC. Finally
the PCR product was treated with 1 ml DpnI endonuclease for 2 h at
37uC, and 2 ml DpnI-digested DNA was transformed into 50 ml
DH5a competent bacteria. Colonies were picked for plasmid
isolation (QIAGEN, Valencia, CA), and nucleotide sequence analysis
was performed at the DNA Core Facility, M.D. Anderson Cancer
Center (Houston, TX).
ELISA assay
GST fusion proteins of wild-type IL-11, alanine scan mutants of
amino acids 112 to 117 of IL-11, or GST alone were coated
overnight onto 96-well plates at 5 mg/ml. Recombinant IL-11 was
added at 2 mg/ml. Wells were subsequently rinsed with wash
buffer (0.1% Tween in PBS), followed by incubation with a
blocking buffer (3% BSA in PBS) for 1 h at room temperature
(RT). IL-11Ra (1 mg/ml) was added and incubated for 2 h.
Binding was detected with anti-human Fc HRP-conjugated
antibody (1:5000). To confirm adequacy of coating, we performed
parallel ELISAs with anti-GST antibody (1:1500, data not shown).
Leptin receptor was used as Fc protein and binding specificity
control.
Alanine-scanning mutagenesis of phage-displayed
peptides
DNA sequences encoding residue substitutions were introduced
into the peptide CGRRAGGSC as indicated. Self-annealing
synthetic oligonucleotides (Sigma-Genosys, Woodlands, TX) were
combined and resuspended in annealing buffer (10 mM Tris-HCl
pH 8.0, containing 100 mM NaCl and 1 mM EDTA) at 10 nM.
Oligonucleotide mixtures were heated to 100uC for 5 min and
cooled down to RT over a 30 min. Self-annealed oligonucleotides
were directly cloned into SfiI-digested fUSE5 vector by using T4
DNA ligase (Roche Applied Science, Indianapolis, IN). Alterna-
tively, 500 ng of the synthetic oligonucleotide templates encoding
the displayed peptides were converted to double-stranded DNA by
PCR amplification with the primer set 59-GTGAG-
CCGGCTGCCC-39 and 59-TTCGGCCCCAGCGGC-39,a n d
Taq-DNA polymerase (Promega, Madison, WI). Double-stranded
PCR products were treated with the restriction enzyme BglII and
were cloned into the SfiI-digested fUSE5 vector. In all cases,
plasmids were transformed into competent DH5a E. coli, and DNA
was verified by sequencing. Oligonucleotides used for the
mutational studies were: CARRAGGSC-forward, 59-
GGGCTTGTGCGCGGAGGGCGGGCGGTTCGTGTGGG-
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GAACCGCCCGCCCTCCGCGCACAAGCCCCGT-39; CGA-
RAGGSC-forward, 59-GGGCTTGTGGGGCGAGGGCGGG-
CGGTTCGTGTGGGGCCGCTG-39; CGARAGGSC-reverse,
59-CGGCCCCACACGAACCGCCCGCCCTCGCCCCACAA-
GCCCCGT-39; CGRAAGGSC-forward, 59-GGGCTTGT-
GGGCGGGCGGCGGGCGGTTCGTGTGGGGCCGCTG-39;
CGRAAGGSC-reverse, 59-CGGCCCCACACGAACCGCCCG-
CCGCCCGCCCACAAGCCCCGT-39; CGRRAAGSC-forward,
59-GGGCTTGTGGGCGGAGGGCGGCGGGTTCGTGTGG-
GGCCGCTG-39; CGRRAAGSC-reverse, 59-CGGCCCCACAC-
GAACCCGCCGCCCTCCGCCCACAAGCCCCGT-39; CGR-
RAGASC-forward, 59-GGGCTTGTGGGCGGAGGGCGGGC-
GCGTCGTGTGGGGCCGCTG-39; CGRRAGASC-reverse, 59-
CGGCCCCACACGACGCGCCCGCCCTCCGCCCACAAG-
CCCCGT-39; CGRRAGGAC-forward, 59-GGGCTTGTGGG-
CGGAGGGCGGGCGGTGCGTGTGGGGCCGCTG-39; CG-
RRAGGAC-reverse, 59-CGGCCCCACACGCACCGCCCGCC-
CTCCGCCCACAAGCCCCGT-39.
Phage binding with the alanine-scanning displaying phage were
performed as described above. Insertless and IL-11-like phage
served as a negative and positive control. All experiments were
performed in duplicate and repeated at least four times with
similar results.
Cell culture and proliferation
Growth factor-dependent erythroleukemia cells (TF-1) were
obtained from the American Type Culture Collection (ATCC;
Manassas, VA) and were cultured in RPMI-1640 containing L-
glutamine, sodium bicarbonate, glucose, HEPES, sodium pyru-
vate, 10% FBS, and 2 ng/ml recombinant GM-CSF (R&D
Systems). EF43.fgf-4, which served as control cells unless otherwise
specified, were maintained in DMEM containing high glucose and
10% FBS. Cell proliferation was measured by metabolic
conversion of WST-1 to formazan (Roche). Cells were incubated
in 96-well dishes (30,000 cells/well) with RPMI-1640 containing
1% FBS plus 3, 10, 30, 100, 300, or 1,000 mM CGRRAGGSC
and/or recombinant human IL-11 (0.5 ng/ml) at 37uC for 72 h.
GM-CSF (0.01 ng/ml) served as a positive control for prolifera-
tion, and an unrelated peptide (CGSPGWVRC) was used as a
negative control. Inhibition of CGRRAGGSC-induced cell
proliferation was assessed in the presence of 100 ng/ml of either
human sIL-11Ra or soluble leptin receptor (negative control).
STAT3 activation assay
TF-1 cells (750,000 cells/well, 24-well dishes) were incubated
18–24 hr in serum-free RPMI-1640. Subsequently,
CGRRAGGSC or negative control peptide (100 mM each), either
alone or in combination with human IL-11 (10 ng/ml), was added
for 15 min. For experiments measuring concentration-depen-
dence, the concentrations were 3, 10, 30 and 100 mM (peptides) or
3, 10, 30 and 100 ng/ml (IL-11). Cells were centrifuged, extracts
were solubilized with Laemmli sample buffer containg ß-
mercatptoethanol, lysates were resolved on 4–20% gradient
SDS-PAGE gels and bands were transferred onto nitrocellulose
membranes (Bio-Rad, Hercules, CA). Membranes were blocked
and subsequently incubated with anti-STAT3 or anti-phospho-
STAT3 (P-Tyr
705) antibodies (1:1,000) followed by HRP-coupled
anti-rabbit antibody (1:2000; Bio-Rad). Detection was by ECL
(Amersham). Commercial HeLa cell extracts treated or not treated
with interferon-a (Cell Signaling) served as controls.
Supporting Information
Figure S1 The IL-11 mimic peptide CGRRAGGSC is multi-
conformational and monomeric (A) Amide region of the 1D-1H-
NMR of CGRRAGGSC peptide (400 mM) at 25uC and at 5uC.
(B) The amide regions of 1D-1H-NMR spectra under increasing
concentrations of the IL-11-like peptide CGRRAGGSC at 25uC
are shown. The presence of broad lines indicates peptide
conformational exchange. No peptide oligomerization induced
by increasing concentrations of CGRRAGGSC (up to 400 mM)
was observed under the experimental conditions used.
Found at: doi:10.1371/journal.pone.0003452.s001 (0.53 MB TIF)
Table S1 Chemical shift for the IL-11-like peptide
Found at: doi:10.1371/journal.pone.0003452.s002 (0.05 MB
DOC)
Table S2 Chemical shift for new resonances in CGRRAGGSC
Found at: doi:10.1371/journal.pone.0003452.s003 (0.03 MB
DOC)
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